Summary
This prediction ended on 06.02.15 with a price of €124.95. The BUY prediction by gerihouse finished with a performance of 12.72%. gerihouse has 50% into this predictionBayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Bayer AG | 1.778% | 1.778% | -44.837% | -41.255% |
iShares Core DAX® | 1.663% | 6.945% | 18.807% | 17.549% |
iShares Nasdaq 100 | 1.261% | 4.883% | 23.667% | 36.206% |
iShares Nikkei 225® | 0.654% | 10.007% | 15.047% | 9.552% |
iShares S&P 500 | 1.403% | 4.350% | 23.305% | 38.641% |
According to gerihouse what are the pros and cons of Bayer AG for the foreseeable future?
Pros
Cons
Comments by gerihouse for this prediction
In the thread Bayer AG diskutieren
Unternehmenswachstum
Bayer sollte jetzt auch wieder zulegen. 3 Kaufempfehlungen in den letzten Tagen
Das US-Analysehaus Bernstein Research hat das Kursziel für Bayer von 123 auf 125 Euro angehoben und die Einstufung auf "Outperform" belassen. Nur weil die Aktien 2014 gut gelaufen seien, müsse das nicht das Ende der guten Kursentwicklung bedeuten, schrieb Analyst Jeremy Redenius in einer Studie vom Montag. Der Pharma- und Chemiekonzern profitiere unter anderem von der Schwäche des Euro. Zudem überzeuge das nachhaltige Unternehmenswachstum./mis/tav